ZTS
Zoetis Inc.
$80.04
+0.57% 2026-10-20
Health CareS&P 500
ZTSSPY
1W
+7.7%
1M
+12.1%
3M
+6.2%
6M
-31.8%
YTD
-35.4%
1Y
-43.8%
Live chart
Loading live chart…
Grades vs sector
Momentum4th pct in sectorF
Momentum
4th pct in sector
12-1 return: -50.8%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth10th pct in sectorD-
Growth
10th pct in sector
Revenue growth (YoY): -0.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value78th pct in sectorB+
Value
78th pct in sector
Forward E/P: 8.2% · EBITDA/EV: 10.1%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability92nd pct in sectorA
Profitability
92nd pct in sector
Profit margin: +27.7% · Return on equity: +64.9%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15rank 491 of 499 · 12-1 momentum % -46.3
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsKey stats
Market cap$33.1B
P/E (trailing)13.2
P/E (forward)12.2
52-week range68.77 – 148.30
Revenue growth (YoY, latest qtr)-0.2%
Dividend yield2.66%
Analyst consensusBuy (14)
Mean price target$94.43 (+18%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Leans undervalued
Model read-out from the numbers below, not advice. Score +2 (DCF counts double).
•DCF (base case)above the price by 10%
▲Forward P/E vs sector12.2x vs median 17.6x
•Piotroski F-score5/9
▲Analyst target+18% (14 analysts)
Discounted cash flow
Bear
$46
-42%
growth -2% · disc. 8.9% · term. 2.0%
Base
$88
+10%
growth 3% · disc. 8.0% · term. 2.5%
Bull
$153
+91%
growth 6% · disc. 7.0% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 2% a year for 10 years.
Implied
+2%/yr
FCF, last 3 yrs
+20%/yr
FCF, last 5 yrs
+6%/yr
Revenue, last 3 yrs
+5%/yr
Revenue, last 5 yrs
+7%/yr
Same inputs as the DCF above: trailing free cash flow 2.3B, 8.0% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.74 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 9th pct
13.2×cheaper
Forward P/E
cheaper
sector median 17.6× · 25th pct
12.2×cheaper
EV / EBITDA
sector median 15.8×
–Price / sales
pricier
sector median 3.1× · 56th pct
3.5×pricier
Price / book
pricier
sector median 3.5× · 88th pct
10.5×pricier
FCF yield
cheaper
sector median 4.1% · 84th pct
7.0%cheaper
Forward EPS $6.55 vs trailing $6.08 (+8% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
71.7%
Operating margin
–
FCF margin
24.3%
Net margin
27.7%
Return on equity
83.8%
Return on invested capital
–
Net debt / EBITDA
–
Current ratio
3.1×
Interest cover
–
Cash conversion (OCF/NI)
1.1×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved
Analysts
Mean target
$94
+18%
Analysts
14
Buy
Range
$74–$155
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $9.5B | $2.7B | $2.3B |
| 2024 | $9.3B | $2.5B | $2.3B |
| 2023 | $8.5B | $2.3B | $1.6B |
| 2022 | $8.1B | $2.1B | $1.3B |
| 2021 | $7.8B | $2.0B | $1.7B |
| 2020 | $6.7B | $1.6B | $1.7B |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +5.4%.
Earnings
Next report: 2026-11-05 · before open · EPS est 1.51
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | 1.85 | 1.87 | +0.9% |
| 2026-05-07 | 1.62 | 1.53 | -5.3% |
| 2026-02-12 | 1.40 | 1.48 | +5.5% |
| 2025-11-04 | 1.62 | 1.70 | +4.8% |
| 2025-08-05 | 1.61 | 1.76 | +9.2% |
| 2025-05-06 | 1.40 | 1.48 | +5.8% |
| 2025-02-13 | 1.36 | 1.40 | +2.8% |
| 2024-11-04 | 1.46 | 1.58 | +8.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $2.5B | -0.2% |
| 2026-03-31 | $2.3B | – |
| 2025-12-31 | $2.4B | – |
| 2025-09-30 | $2.4B | – |
| 2025-06-30 | $2.5B | – |
Analyst actions
Jefferies
PT $83
2026-10-20 · down
Buy → HoldPT $83
Goldman Sachs
PT $74
2026-10-16 · init
→ NeutralPT $74
TD Cowen
PT $94
2026-08-25 · main
Buy → BuyPT $94
Stifel
PT $80
2026-08-20 · main
Hold → HoldPT $80
Citigroup
PT $96
2026-08-11 · main
Buy → BuyPT $96
BNP Paribas
PT $110
2026-08-11 · main
Outperform → OutperformPT $110
Recent dividends
2026-07-20: $0.530 · 2026-04-20: $0.530 · 2026-01-20: $0.530 · 2025-10-31: $0.500 · 2025-07-18: $0.500 · 2025-04-21: $0.500 · 2025-01-21: $0.500 · 2024-10-31: $0.432
Insider trades
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:02:53 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteauCoteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.